Notícias e Atividades da Debiopharm Research & Manufacturing

A Debiopharm Research & Manufacturing pertence à Debiopharm International.

Eles estão dentro:

• Farmacêutica67%
• Biotecnologia33%

Veja o organograma con seus 11 executivos principais

Biografias mais buscadas da Debiopharm Research & Manufacturing

• Cédric Sager, Chief Executive Officer
• Liem Vu Thanh, Quality Assurance Director
• Celine Anselmetti Dayer, Director of Regulatory Affairs

Criar um alerta
para seguir os movimentos de executivos da Debiopharm Research & Manufacturing.

Debiopharm International possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Debiopharm Research & Manufacturing

• Press Releases - Debiopharm
• Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer - Debiopharm
• Debiopharm to unveil new pre-clinical and clinical research advances in DDR inhibition, dual payload ADCs, and AI-driven biomarkers at AACR 2026 - Debiopharm
• GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug - Debiopharm
• StudentsPool fait rayonner l’innovation patients en remportant le 10ᵉ Challenge Qualité de vie du patient et reçoit le prix de 25'000 francs - Debiopharm
• Redefining Acromegaly Care: First Patient Randomized in Debiopharm's Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment - Debiopharm
• Debiopharm Leverages Risklick's AI-Powered Solution to Improve Protocol Development Efficiency - Debiopharm
• Swiss-Based Debiopharm Seeks To Boost Innovation In Japanese Cancer Research Through The New "Ideal Japan” Program - Debiopharm
• Debiopharm Takes a Step Forward for Children with CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation - Debiopharm
• Debiopharm Forges AI-Powered Alliance with NetTargets to Pioneer Dual-Payload ADCs Against Drug-Resistant Cancers - Debiopharm
• View more press releases Close

Redes sociais sobre Debiopharm Research & Manufacturing

• Debiopharm Research & Manufacturing na Wikipedia, Google News e Yahoo Finance
• Debiopharm Research & Manufacturing na LinkedIn, X (Twitter) e YouTube